Economic Evaluation of cabazitaxel (Jevtana®) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.
|02/06/2011||09/06/2011||Full Pharmacoeconomic Evaluation Recommended.|
|03/11/2011||13/03/2012||Reimbursement not recommended at the submitted price.|
The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.
The HSE has approved reimbursement following confidential price negotiations.